{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:18:03Z","timestamp":1788556683187,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jagp.2022.08.007","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:33:00Z","timestamp":1662438780000},"page":"44-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns"],"prefix":"10.1016","volume":"31","author":[{"given":"C. Bree","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2022.08.007_bib0001","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and Psychedelic-Assisted Psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0002","series-title":"Psychiatry May Never be the Same","article-title":"The Psychedelic Revolution is Coming","author":"Jacobs","year":"2021"},{"key":"10.1016\/j.jagp.2022.08.007_bib0003","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/bcp.14539","article-title":"Underrepresentation of the elderly in clinical trials, time for action","volume":"86","author":"van Marum","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0004","series-title":"Handbook of Medical Hallucinogens","first-page":"29","article-title":"Anthropology, Shamanism, and Hallucinogens","author":"Winkelman","year":"2021"},{"key":"10.1016\/j.jagp.2022.08.007_bib0005","series-title":"Handbook of Medical Hallucinogens","first-page":"68","article-title":"A Short, Strange Trip: LSD Politics, publicity, and mythology - From discovery to criminalization","author":"Mangini","year":"2021"},{"key":"10.1016\/j.jagp.2022.08.007_bib0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jagp.2022.08.007_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1310-3990","article-title":"The History of Psychedelics in Psychiatry","volume":"54","author":"Nichols","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.jagp.2022.08.007_bib0008","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.jagp.2022.08.007_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/2054.2019.032","article-title":"Diversity, equity, and access in psychedelic medicine","volume":"4","author":"Williams","year":"2019","journal-title":"J Psychedelic Stud"},{"key":"10.1016\/j.jagp.2022.08.007_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.jagp.2022.08.007_bib0011","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2125.2000.00121.x","article-title":"Non-linear pharmacokinetics of MDMA ('ecstasy') in humans","volume":"49","author":"de la Torre","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0012","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2013.11.008","article-title":"Monoamine transporter and receptor interaction profiles of a new series of designer cathinones","volume":"79","author":"Simmler","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jagp.2022.08.007_bib0013","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0014","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/rapm-2020-101273","article-title":"Chronic pain and psychedelics: a review and proposed mechanism of action","volume":"45","author":"Castellanos","year":"2020","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.jagp.2022.08.007_bib0018","first-page":"1","article-title":"Assessing the risk\u2013benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research","author":"Bender","year":"2022","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0019","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","article-title":"Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","volume":"237","author":"Jerome","year":"2020","journal-title":"Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jagp.2022.08.007_bib0020","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/0269881117691569","article-title":"Safety pharmacology of acute MDMA administration in healthy subjects","volume":"31","author":"Vizeli","year":"2017","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0021","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0022","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jagp.2022.08.007_bib0023","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","article-title":"Adverse reactions to psychedelic drugs: A review of the literature","volume":"127","author":"Strassman","year":"1984","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.jagp.2022.08.007_bib0024","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: Safety and ethical concerns","volume":"7","author":"BT","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0025","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0026","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0022167817706884","article-title":"Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis","volume":"57","author":"Belser","year":"2017","journal-title":"J Humanist Psychol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0027","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/2012.jama.10690","article-title":"Older adults with severe, treatment-resistant depression","volume":"308","author":"Unutzer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2022.08.007_bib0028","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jad.2010.11.033","article-title":"Age- and gender-specific prevalence of depression in latest-life\u2013systematic review and meta-analysis","volume":"136","author":"Luppa","year":"2012","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jagp.2022.08.007_bib0029","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.14336\/AD.2021.0526","article-title":"Depression and Dementia in Older Adults: A Neuropsychological Review","volume":"12","author":"Tetsuka","year":"2021","journal-title":"Aging Dis"},{"key":"10.1016\/j.jagp.2022.08.007_bib0030","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jagp.2019.04.005","article-title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized","volume":"27","author":"Cristancho","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0031","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.JGP.0000194645.70869.3b","article-title":"A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression","volume":"14","author":"Schatzberg","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-10-1","article-title":"Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons","volume":"10","author":"Bartlett","year":"2009","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.jagp.2022.08.007_bib0033","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/WNF.0b013e31823337d1","article-title":"Unraveling the association between SSRI use and falls: an experimental study of risk factors for accidental falls in long-term paroxetine users","volume":"34","author":"Hegeman","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0034","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0036","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jagp.2022.08.007_bib0037","unstructured":"Mortality in the United States, 2019, NCHS Data Brief No. 395 (online). Available at cdc.gov\/nchs\/products\/databriefs\/db395.htm. Accessed April 1, 2022"},{"key":"10.1016\/j.jagp.2022.08.007_bib0038","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jpainsymman.2014.07.008","article-title":"A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: A decade of research","volume":"49","author":"Robinson","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jagp.2022.08.007_bib0039","first-page":"29","article-title":"Mental health care in oncology. Contemporary perspective on the psychosocial burden of cancer and evidence-based interventions","author":"Caruso","year":"2020","journal-title":"Epidemiology and Psychiatric Sciences"},{"key":"10.1016\/j.jagp.2022.08.007_bib0040","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1200\/JCO.2011.39.7372","article-title":"Evidence-based treatment of depression in patients with cancer","volume":"30","author":"Li","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0041","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/pon.4829","article-title":"Effects of existential interventions on spiritual, psychological, and physical well-being in adult patients with cancer: Systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Bauereiss","year":"2018","journal-title":"Psycho-oncology"},{"key":"10.1016\/j.jagp.2022.08.007_bib0042","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1200\/JCO.2011.40.8922","article-title":"Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis","volume":"31","author":"Faller","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0043","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jagp.2022.08.007_bib0044","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0046","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jagp.2022.08.007_bib0048","doi-asserted-by":"crossref","first-page":"20442","DOI":"10.1038\/s41598-020-75706-1","article-title":"MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study","volume":"10","author":"Wolfson","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jagp.2022.08.007_bib0049","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cbpra.2010.10.002","article-title":"Treatment of PTSD in older adults: Do cognitive-behavioral interventions remain viable?","volume":"19","author":"Clapp","year":"2012","journal-title":"Cogn Behav Pract"},{"key":"10.1016\/j.jagp.2022.08.007_bib0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jagp.2013.01.064","article-title":"PTSD is a chronic, fluctuating disorder affecting the mental quality of life in older adults","volume":"22","author":"Chopra","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113964","article-title":"Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSD","volume":"301","author":"N\u00f8hr","year":"2021","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.jagp.2022.08.007_bib0052","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jagp.2022.08.007_bib0053","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/j.1532-5415.2006.00843.x","article-title":"Tobacco cessation counseling across the ages","volume":"54","author":"Wallace","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2022.08.007_bib0054","series-title":"Geriatric Medicine and Gerontology seventh edition","first-page":"1095","article-title":"General Topics in Geriatric Psychiatry","author":"Sewell","year":"2017"},{"key":"10.1016\/j.jagp.2022.08.007_bib0055","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jagp.2022.08.007_bib0056","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3, 4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0057","article-title":"Psychedelics as a Treatment for Alzheimer's Disease Dementia","volume":"12","author":"Vann Jones","year":"2020","journal-title":"Front Synaptic Neurosci"},{"key":"10.1016\/j.jagp.2022.08.007_bib0058","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/7854_2021_267","article-title":"Psychedelics as Novel Therapeutics in Alzheimer\u2019s Disease: Rationale and Potential Mechanisms","volume":"56","author":"Garcia-Romeu","year":"2021","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.jagp.2022.08.007_bib0059","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/lm.60803","article-title":"Role of the serotonin 5-HT2A receptor in learning","volume":"10","author":"Harvey","year":"2003","journal-title":"Learning & Memory"},{"key":"10.1016\/j.jagp.2022.08.007_bib0060","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/02791072.2020.1761573","article-title":"The viability of microdosing psychedelics as a strategy to enhance cognition and well-being - an early review","volume":"52","author":"Bornemann","year":"2020","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.jagp.2022.08.007_bib0061","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","article-title":"Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study","volume":"288","author":"Lyketsos","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2022.08.007_bib0062","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/156720508783884585","article-title":"Prevalence of neuropsychiatric symptoms in Alzheimer's disease and vascular dementia","volume":"5","author":"Fernandez-Martinez","year":"2008","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jagp.2022.08.007_bib0063","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2021.4201","article-title":"Prolonged Grief Disorder Diagnostic Criteria\u2014Helping Those With Maladaptive Grief Responses","author":"Prigerson","year":"2022","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0064","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00213-019-05446-2","article-title":"Therapeutic potential of ayahuasca in grief: a prospective, observational study","volume":"237","author":"Gonz\u00e1lez","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jagp.2022.08.007_bib0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/ACM.0000000000001294","article-title":"Structural vulnerability: operationalizing the concept to address health disparities in clinical care. Academic Medicine","volume":"92","author":"Bourgois","year":"2017","journal-title":"J Assoc Am Med Coll"},{"key":"10.1016\/j.jagp.2022.08.007_bib0066","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0067","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/act.2020.29309.apb","article-title":"Psilocybin, Spirituality, and Palliative Care: Research and Implications","volume":"27","author":"Bossis","year":"2021","journal-title":"Alternative and Complementary Therapies"},{"key":"10.1016\/j.jagp.2022.08.007_bib0068","series-title":"Oxford Textbook of Spirituality in Healthcare","first-page":"353","article-title":"Spiritual well-being scale: Mental and physical health relationships","author":"Paloutzian","year":"2014"},{"key":"10.1016\/j.jagp.2022.08.007_bib0069","unstructured":"Ageing and Health Fact Sheet. 2021, World Health Organization (online). Available at: who.int\/news-room\/fact-sheets\/detail\/ageing-and-health. Accessed April 2, 2022"},{"key":"10.1016\/j.jagp.2022.08.007_bib0070","unstructured":"Healthy People 2020, Older Adults (online). Available athealthypeople.gov\/2020\/topics-objectives\/topic\/older-adults#2. Accessed April 2, 2020"},{"key":"10.1016\/j.jagp.2022.08.007_bib0071","article-title":"Hypertension Prevalence amondt adults aged 18 and over: United States, 2017-2018","volume":"364","author":"Ostchega","year":"2020","journal-title":"NCH Data Brief N"},{"key":"10.1016\/j.jagp.2022.08.007_bib0072","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881121991822","article-title":"GriffithsRR. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches","volume":"35","author":"Garcia-Romeu","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.08.007_bib0073","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cpdd.796","article-title":"Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin\/Psilocin","volume":"10","author":"Dahmane","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jagp.2022.08.007_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics","volume":"12","author":"de Vos","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jagp.2022.08.007_bib0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neurobiolaging.2021.03.013","article-title":"Default mode network connectivity and cognition in the 47aging brain: the effects of age, sex, and APOE genotype","volume":"104","author":"Shafer","year":"2021","journal-title":"Neurobiol Aging"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748122005012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748122005012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:34:14Z","timestamp":1761021254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748122005012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1064748122005012"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2022.08.007","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2022.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}